Shire PLC (SHP) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Shire PLC (LON:SHP) have been given a consensus recommendation of “Buy” by the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 5,472.59 ($72.22).
Several research firms have recently commented on SHP. J P Morgan Chase & Co restated an “overweight” rating and set a GBX 5,300 ($69.94) price target on shares of Shire PLC in a research report on Monday. Liberum Capital lowered their price target on shares of Shire PLC from GBX 4,400 ($58.06) to GBX 4,200 ($55.42) and set a “hold” rating for the company in a research report on Tuesday, October 24th. Deutsche Bank AG lowered their price target on shares of Shire PLC from GBX 6,000 ($79.18) to GBX 5,700 ($75.22) and set a “buy” rating for the company in a research report on Tuesday, September 5th. Barclays PLC restated an “equal weight” rating and set a GBX 4,000 ($52.78) price target on shares of Shire PLC in a research report on Monday. Finally, Credit Suisse Group restated an “outperform” rating and set a GBX 5,350 ($70.60) price target on shares of Shire PLC in a research report on Tuesday, August 22nd.
In other news, insider Flemming Ornskov acquired 8,400 shares of Shire PLC stock in a transaction on Tuesday, August 22nd. The stock was bought at an average cost of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95). Also, insider Anne Minto acquired 190 shares of Shire PLC stock in a transaction on Friday, September 29th. The shares were purchased at an average cost of GBX 3,785 ($49.95) per share, with a total value of £7,191.50 ($9,489.97).
TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/02/shire-plc-shp-receives-consensus-recommendation-of-buy-from-brokerages.html.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.